KEY POINTS
- Doximity shares fell 24% after fiscal Q4 adjusted EPS of $0.26 missed the $0.28 consensus by 7.14%, despite revenue of $145.4 million slightly beating estimates.
- Management guided for just 3-5% revenue growth in FY2027 with adjusted EBITDA margins declining to approximately 49%, driven by surging AI compute costs.
- The selloff highlights a growing tension across the software sector between AI investment demands and near-term profitability expectations.
Doximity shares collapsed 24% on Thursday after the healthcare networking platform delivered a fiscal fourth-quarter earnings report that missed on the bottom line and paired it with forward guidance that spooked even the stock's most committed holders. Adjusted earnings per share of $0.26 fell short of the $0.28 consensus, a 7.14% miss that in a growth stock trading at premium multiples was enough to trigger a stampede for the exits.
Revenue of $145.4 million technically beat expectations, but in the context of what management said about fiscal 2027, that beat was irrelevant.
The Guidance Problem
The number that destroyed the stock was the full-year fiscal 2027 revenue growth forecast of 3% to 5%. For a company that had been growing at double-digit rates and trading on the premise that its physician network would become the dominant platform for digital pharmaceutical advertising, mid-single-digit growth is a fundamental derating event.
Compounding the damage was the margin outlook. Management projected adjusted EBITDA margins declining to approximately 49% for FY2027, down from the mid-50s range that investors had come to expect. The primary driver of compression was increased investment in AI compute, driven by what management described as a "steep ramp in AI usage" across the platform.
This is the AI spending paradox playing out in real time. Doximity is investing heavily in artificial intelligence capabilities to maintain competitive positioning, but the revenue payoff from that investment is not arriving fast enough to offset the cost. The company is spending more to deliver AI-powered features that its customers are using at scale, but it cannot yet monetize that usage at rates sufficient to maintain margins.
The Pharma Ad Market Softens
Management's commentary on the demand environment was equally concerning. The company noted that "short-term demand in the HCP digital pharma ad market is soft," attributing the weakness to elevated policy uncertainty and increased macro risk. This is a direct reference to the regulatory and economic environment facing pharmaceutical companies, which are Doximity's primary customers.
Pharma advertising budgets are among the first discretionary line items to get cut when companies face uncertainty about drug pricing policy, FDA approval timelines, or broader economic conditions. The Iran-driven inflation environment and the political transition at the Federal Reserve are creating exactly the kind of uncertainty that causes pharmaceutical marketing executives to delay spending decisions.
The risk for Doximity is that this is not a one-quarter phenomenon. If pharma ad spending remains soft through the second half of 2026, the company's 3-5% growth guide may prove optimistic rather than conservative. The platform's physician engagement metrics remain strong, but engagement without monetization is a cost center, not a growth engine.
What This Means for the Broader AI Trade
Doximity's selloff carries implications beyond its $3 billion market capitalization. The stock's decline highlights a tension that will define the next phase of the AI investment cycle: companies are being asked to spend aggressively on AI infrastructure and capabilities, but the market is simultaneously demanding that they maintain or expand profit margins.
Cisco resolved that tension on Thursday by showing that AI spending is generating massive order growth. Doximity shows the opposite outcome: AI spending that raises costs without proportionally raising revenue. The distinction matters because most companies in the software sector look more like Doximity than Cisco when it comes to AI monetization. They are investing in the technology because they have to, not because they have found a clear path to returns.
For traders, Doximity's next critical level is the $28-$30 range, which represents pre-AI-hype valuations from early 2024. If the stock stabilizes there, it becomes a value play on an eventual recovery in pharma ad spending. If it breaks below $28, the market is saying the growth story is permanently impaired. Watch the next two quarters of pharma earnings for signals on advertising budget trends. That data will determine whether Doximity's current price is a floor or a waypoint.
